YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
YD Bio reported six-month revenue of $846,501, a 315% year-over-year increase driven by large-scale orders including $327,060 for Fetroja for Injection. The company swung to a net profit of $6.7 million, largely due to a $9.8 million non-cash gain from warrant fair value changes, though operational losses widened to $3.1 million.
Key figures
- Eps
- 0.09
- Revenue
- 846501
- Revenue Yoy
- 315%
- Net income
- 6700497
- Gross profit
- 268230
- Cash position
- 2662004
- Top product revenue
- 327060
- Warrant fair value change
- 9846532
- Ssmc acquisition value usd
- 26870000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.